

Patent claims

1. Formulation in the form of a matrix material-containing compound with an excipient phase with at least one excipient and/or an active substance phase with at least one active substance, characterized in that the matrix material is chosen from polymers and lipids, the polymer phase and/or the lipid phase of the formulation is incoherent and the excipient and/or active substance phase of the formulation is coherent.
2. Formulation according to claim 1, characterized in that the matrix material phase of the formulation comprises excipient and/or active substance or is free therefrom.
3. Formulation according to one of claims 1 or 2, characterized in that the content of the matrix material phase of the formulation is 1 to 98 %.
4. ~~Formulation according to one of claims 1 to 3, characterized in that the content of the matrix material phase of the formulation is 10 to 95 %.~~
Claim 1 wherein
5. ~~Formulation according to one of claims 1 to 4, characterized in that the content of the matrix material phase of the formulation is more than 15 % and not more than 90 %.~~
Claim 1 wherein
6. ~~Formulation according to one of claims 1 to 5, characterized in that the content of the matrix material phase of the formulation is 40 to 70 %.~~
Claim 1
7. ~~Formulation according to one of claims 1 to 6, characterized in that the polymeric phase comprises~~
Claim 1 wherein

5 *CPD*
a polyacrylate and/or a polymethacrylate and/or the
lipid phase comprises naturally occurring, semi-
synthetic and synthetic triglycerides or mixtures
thereof, mono- and diglycerides by themselves or in
a mixture with one another or with triglycerides,
naturally occurring and synthetic waxes, fatty
alcohols, including their esters and ethers, and
lipid peptides, in particular synthetic mono-, di-
and triglycerides as individual substances or in a
mixture, specifically hydrogenated fat, glycerol tri-
fatty acid esters, specifically glycerol trilaurate,
-myristate, -palmitate, -stearate and -behenate, and
waxes, specifically cetyl palmitate and cera alba
(bleached wax, German Pharmacopeia, 9th edition) or
beeswax.

- 10
15
20 8. Formulation according to ~~one of claims 1 to 7,~~
Claim 1, wherein
~~characterized in that~~ the polymer phase comprises a
polyacrylate and/or a polymethacrylate, a cellulose
derivative or naturally occurring polymer and/or the
lipid phase comprises a naturally occurring lipid.

25 *SUB*
GI 9. Formulation according to ~~one of claims 1 to 8,~~
Claim 1, wherein
~~characterized in that~~ it comprises at least one
active substance.

- 30 10. Formulation according to ~~one of claims 1 to 9,~~
Claim 1, wherein
~~characterized in that~~ the excipient phase comprises
at least one filler, in particular chosen from
monosaccharides, disaccharides, polysaccharides,
sugar alcohols and calcium phosphate, and/or at least
one binder, in particular chosen from polyvinyl-
pyrrolidone, gelatine, starch paste, celluloses,
cellulose ethers and sugars.

11. Composition according to ~~one of the preceding claims~~,
characterized in that it is in the form of a com-
pressed unit which can be prepared by direct compres-
sion.

12. Process for the preparation of a formulation in the
form of a matrix material containing compound accord-
ing to ~~one of claims 1 to 11~~, characterized in that
the phases of the formulation are suspended or
suspended and dissolved together in a liquid, the
matrix material phase being insoluble in the liquid,
and this suspension is then spray dried.

13. Process for the preparation of a formulation in the
form of a matrix material containing compound accord-
ing to ~~one of claims 1 to 11~~, characterized in that
the phases of the formulation are suspended or
suspended and dissolved together in a liquid, the
matrix material phase being insoluble in the liquid,
and this suspension is then dried in a moving bed or
fluidized bed drier.

14. Process according to ~~claim 12 or 13~~, characterized in
that the liquid is an aqueous or organic suspending
agent.

15. Process according to ~~one of claims 12 to 14~~, charac-
terized in that at least one binder and/or at least
one wetting agent and/or at least one plasticizer is
added to the suspension.

16. Use of the formulation in the form of a matrix
material containing compound according to ~~one of~~
~~claims 1 to 11~~ for the preparation of larger matrix
units with controlled release properties by known
processes.

of the formulation in the form of a matrix material-containing compound according to one of ~~claims 1 to 11~~ for the preparation of tablets and/or other matrix units with controlled release properties by means of direct compression.

5

 $\text{add } \epsilon'$

Add 64

add
F3

[illegible]